Blood cells are reprogrammed into stem cells with the potential to create every organ of the body. The use of patient cells incorporates the entire personalized genome of any person with any disease.
Mirroring The Brain For Therapies That Work
Pharma loses billions on failed drugs for the treatment of neurological disorders. Consequently, industry has withdrawn from the neuro field, and the exploding medical need remains unmet. The main reasons are that the human brain is poorly understood, and research is mainly based on animals. Thus, conclusions about treatments in people are wrong.
Our Radical Approach
Why not develop drugs in human brain?
We uncover novel CNS therapeutics by employing a proprietary drug development engine with true physiological relevance. Unlike the traditional strategies using molecular targets and animal models, we recreate human disease in CEREBRAL ORGANOIDS. This biomedical revolution fuses cutting edge science using cell reprogramming, gene editing, state-of-the-art 3D culture technology, and digital biology. We apply deep AI-driven analysis to uncover complex disease signatures and push disease model sophistication a:head to create unrivaled opportunities in CNS drug discovery.
Cerebral organoids closely resemble the human brain by following the same developmental stages, generating complex organ-like tissue structure, and creating active neural networks. The 3D tissue architecture found in young brain is recapitulated in vitro providing a complex 3D environment unattainable with 2D culture systems. Moreover, human-specific cell types exist in brain organoids, which highlights their biological relevance over animal-based models.
brain network activity
Patients suffer from disrupted brain function which is measured with electrical recordings. We follow the same principle, and screen human brain network activity outside of humans to find new drugs. Focusing our assays on what is affected in a patient’s brain creates the most clinically relevant drug discovery platform ever envisioned.
we are drug development pioneers:
a:head leaves classic approaches b:hind to realize a new age of efficacious drugs. Our advanced drug discovery engine can be applied universally to multiple CNS diseases and therapeutic modalities. Furthermore, we circumvent irrelevant animal testing with the use of human biology. The a:head platform holds unprecedented predictive power that will lead industry back into the neuro arena. We aim to partner with forward-thinking pharmaceutical and biotech companies to offer hope to patients for whom no treatment exists.
Scientific Advisory Board:
March 3, 2021a:head and 3Brain enter into collaboration on high-density, high-throughput MEA systems
February 22, 2021a:head closes another 7-digit EUR financing round
October 24, 2019a:head signs license and collaboration agreements with IMBA and awarded funding from FFG
August 7, 2019a:head launched to transform CNS drug discovery